Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia

• Status: Terminated
• Trial end date: 2020-10-17
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate the safety and tolerability of AMG 330, administered in combination with pembrolizumab, in participants with relapsed or refractory acute myeloid leukemia (R/R AML).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Pembrolizumab

Criteria

Key Inclusion criteria

• AML as defined by the WHO Classification persisting or recurring following one or more treatment courses. Except APL

• Eastern Cooperative Oncology Group (ECOG) ≤1

Key Exclusion criteria

• Active extramedullary AML in the central nervous system.

• Known hypersensitivity to immunoglobulins.

• Non-manageable graft versus host disease.